Peptide deformylase inhibitors with activity against respiratory tract pathogens

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 1, 2004, Pages 59-62

  East, Stephen P ^a,b   Beckett, R Paul ^a   Brookings, Daniel C ^a   Clements, John M ^a   Doel, Sheila ^a   Keavey, Kenneth ^a   Pain, Gilles ^a   Smith, Helen K ^a   Thomas, Wayne ^a   Thompson, Alison J ^a   Todd, Richard S ^a   Whittaker, Mark ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

^b EVOTEC UK LTD   (United Kingdom)

Author keywords

Antibacterial; Inhibitors; Peptide deformylase

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CIPROFLOXACIN; KETONE; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CATALYSIS; CHEMICAL BOND; CONTROLLED STUDY; ELECTRON TRANSPORT; HAEMOPHILUS INFLUENZAE; HYDROGENATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION;

EID: 0348147640     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.10.013     Document Type: Article

References (20)

1. (a) Pei D. Emerging Ther. Targets. 5:2001;23.
2. (b) Giglione C., Meinnel T. Emerging Ther. Targets. 5:2001;41
3. (c) Yuan Z., Trias J., White R.J. Drug Discov. Today. 6:2001;955.
4. (d) Clements J.M., Ayscough A., Keavey K., East S.P. Curr. Med. Chem. - Anti-Infective Agents. 1:2002;239.
5. (a) Adams J.M., Capecchi M. Proc. Natl. Acad. Sci. U.S.A. 55:1966;147.
6. (b) Adams J.M. J. Mol. Biol. 33:1968;571.
7. Smith H.K., Beckett R.P., Clements J.M., Doel S., East S.P., Launchbury S.B., Pratt L.M., Spavold Z.M., Thomas W., Todd R.S., Whittaker M. Bioorg. Med. Chem. Lett. 12:2002;3595.
8. (a) Davies S.J., Ayscough A.P., Beckett R.P., Bragg R.A., Clements J.M., Doel S., Grew C., Launchbury S.B., Perkins G.M., Pratt L.M., Smith H.K., Spavold Z.M., Thomas S.W., Todd R.S., Whittaker M. Bioorg. Med. Chem. Lett. 13:2003;2709
9. (b) Davies S.J., Ayscough A.P., Beckett R.P., Clements J.M., Doel S., Pratt L.M., Spavold Z.M., Thomas S.W., Whittaker M. Bioorg. Med. Chem. Lett. 13:2003;2715.
10. The tertiary alcohol, general formula 14, resulting from double addition of the metallated species to Pfp ester 3 was usually detected as a side product (typically ~10%) in this reaction.
11. Pratt L.M., Beckett R.P., Davies S.J., Launchbury S.B., Miller A., Spavold Z.M., Todd R.S., Whittaker M. Bioorg. Med. Chem. Lett. 11:2001;2585.
12. Full experimental details on individual compounds can be found in the patent literature. International publication number: WO 00/61134.
13. The natural ferrous-containing PDF enzyme oxidises readily to the inactive ferric form. Consequently, for ease of experimentation, we routinely test against the stable nickel-containing enzyme that retains full catalytic activity.
14. For details of the PDF inhibition and microbiological assays see: Clements J.M., Beckett R.P., Brown A., Catlin G., Lobell M., Palan S., Thomas W., Whittaker M., Wood S., Salama S., Baker P.J., Rodgers H.F., Barynin V., Rice D.W., Hunter M.G. Antimicrob. Agents Chemother. 45:2001;563.
15. Barbachyn M.R., Ford C.W. Angew. Chem., Int. Ed. 42:2003;2010.
16. Koga H., Itoh A., Murayama S., Suzue S., Irikura T. J. Med. Chem. 23:1980;1258.
17. 19F NMR experiments. Only the 2-aminoaryl ketones were isolated following purification.
18. Margolis P., Hackbath C., Lopez S., Maniar M., Wang W., Yuan Z., White R., Trias J. Antimicrob. Agents Chemother. 45:2001;2432.
19. All compounds were tested against an fmt mutant strain of S. aureus and shown to have an MIC gt;32 μg/mL. From this result we infer that PDF inhibition is the mechanism of action.
20. Wise R., Andrews J.M., Ashby J. Antimicrob. Agents Chemother. 46:2002;1117.